II期临床研究-话题@MedSci

#II期临床研究#

109篇内容 | 2948人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1649979, encodeId=3a7016499e998, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, objectType=article, longId=141928, objectId=2c18141928fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c18141928fb, replyNumber=0, likeNumber=74, createdTime=2018-10-24, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c18141928fb, moduleTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c18141928fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649972, encodeId=059416499e267, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, objectType=article, longId=113798, objectId=4275113e9856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4275113e9856, replyNumber=0, likeNumber=85, createdTime=2018-02-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4275113e9856, moduleTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4275113e9856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649976, encodeId=3cb916499e607, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, objectType=article, longId=125930, objectId=85ca1259307a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ca1259307a, replyNumber=0, likeNumber=56, createdTime=2018-06-13, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ca1259307a, moduleTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ca1259307a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649977, encodeId=e81016499e7cf, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, objectType=article, longId=130729, objectId=edaa130e2993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edaa130e2993, replyNumber=0, likeNumber=63, createdTime=2018-10-22, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edaa130e2993, moduleTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edaa130e2993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649975, encodeId=388716499e556, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, objectType=article, longId=122745, objectId=1ede122e4567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ede122e4567, replyNumber=0, likeNumber=40, createdTime=2018-11-15, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ede122e4567, moduleTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ede122e4567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649968, encodeId=6005164996884, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, objectType=article, longId=102825, objectId=3eb2102825e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eb2102825e6, replyNumber=0, likeNumber=0, createdTime=2018-05-19, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eb2102825e6, moduleTitle=Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eb2102825e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649974, encodeId=d4a616499e4fd, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, objectType=article, longId=117236, objectId=41dc11e236e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41dc11e236e9, replyNumber=0, likeNumber=64, createdTime=2018-02-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41dc11e236e9, moduleTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41dc11e236e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649973, encodeId=c21216499e31f, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=NEJM：埃博拉疫苗III期临床研究, objectType=article, longId=115953, objectId=514d11595351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514d11595351, replyNumber=0, likeNumber=55, createdTime=2017-12-10, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514d11595351, moduleTitle=NEJM：埃博拉疫苗III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=514d11595351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649971, encodeId=5c8e16499e120, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, objectType=article, longId=107571, objectId=185210e571e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185210e571e9, replyNumber=0, likeNumber=56, createdTime=2018-03-25, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185210e571e9, moduleTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185210e571e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649970, encodeId=7e9616499e05c, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, objectType=article, longId=107035, objectId=461b10e035bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461b10e035bf, replyNumber=0, likeNumber=55, createdTime=2018-06-14, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461b10e035bf, moduleTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461b10e035bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649969, encodeId=d3f0164996943, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, objectType=article, longId=103410, objectId=211c103410c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=211c103410c6, replyNumber=0, likeNumber=136, createdTime=2018-06-01, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=211c103410c6, moduleTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=211c103410c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649967, encodeId=5ed2164996eaa, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, objectType=article, longId=93569, objectId=376693569b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376693569b4, replyNumber=0, likeNumber=62, createdTime=2017-05-06, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376693569b4, moduleTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376693569b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649965, encodeId=aed3164996571, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, objectType=article, longId=56015, objectId=17c9560153c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17c9560153c, replyNumber=0, likeNumber=63, createdTime=2016-02-03, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17c9560153c, moduleTitle=招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17c9560153c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649966, encodeId=0b341649966b7, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, objectType=article, longId=56019, objectId=a3645601997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3645601997, replyNumber=0, likeNumber=69, createdTime=2016-02-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3645601997, moduleTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3645601997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649962, encodeId=7d201649962c2, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Lancet Oncol：帕唑帕尼加每周紫杉醇用于晚期卵巢癌的II期临床研究, objectType=article, longId=50354, objectId=7a1c50354b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a1c50354b4, replyNumber=0, likeNumber=84, createdTime=2015-12-28, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a1c50354b4, moduleTitle=Lancet Oncol：帕唑帕尼加每周紫杉醇用于晚期卵巢癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a1c50354b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649964, encodeId=6415164996473, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究, objectType=article, longId=56009, objectId=dfa856009e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa856009e2, replyNumber=0, likeNumber=0, createdTime=2015-11-06, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa856009e2, moduleTitle=招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfa856009e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649963, encodeId=bbb01649963e5, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效, objectType=article, longId=51623, objectId=b8435162302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8435162302, replyNumber=0, likeNumber=84, createdTime=2016-02-20, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8435162302, moduleTitle=ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8435162302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649960, encodeId=edf1164996083, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, objectType=article, longId=47689, objectId=936f4e689f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=936f4e689f6, replyNumber=0, likeNumber=92, createdTime=2015-11-17, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=936f4e689f6, moduleTitle=Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=936f4e689f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649959, encodeId=a4fe164995979, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Clin Cancer Res：尼罗替尼对KIT突变的黑色素瘤的II期临床研究, objectType=article, longId=47422, objectId=08b34e422c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08b34e422c6, replyNumber=0, likeNumber=58, createdTime=2015-05-02, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08b34e422c6, moduleTitle=Clin Cancer Res：尼罗替尼对KIT突变的黑色素瘤的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08b34e422c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1649961, encodeId=961e1649961b6, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, objectTitle=Clin Cancer Res：Palbociclib 对Rb+晚期乳腺癌的II期临床研究, objectType=article, longId=48832, objectId=5c1248832b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c1248832b6, replyNumber=0, likeNumber=62, createdTime=2015-07-26, rootId=0, userName=huiwelcome, userId=891023951385, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c1248832b6, moduleTitle=Clin Cancer Res：Palbociclib 对Rb+晚期乳腺癌的II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c1248832b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床研究

2020-05-29

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

安进公司宣布生物仿制药ABP 710的III期临床研究结果

2018-10-24

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

肾性贫血首创药罗沙司他III期临床研究结果发布

2018-02-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究

2018-06-13

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究

2018-10-22

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性

2018-11-15

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Ann Oncol：卡铂和紫杉醇联合依维莫司可作为转移性肺大细胞神经内分泌癌患者的一线治疗（多中心II期临床研究）

2018-05-19

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究

2018-02-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

NEJM：埃博拉疫苗III期临床研究

2017-12-10

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究

2018-03-25

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险

2018-06-14

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）

2018-06-01

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究

2017-05-06

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

招募患者：马来酸吡咯替尼片联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2表达阳性转移性乳腺癌的I/II期临床研究

2016-02-03

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究

2016-02-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Lancet Oncol：帕唑帕尼加每周紫杉醇用于晚期卵巢癌的II期临床研究

2015-12-28

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究

2015-11-06

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效

2016-02-20

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Ann Oncol：MEK抑制剂trametinib对KRAS突变的非小细胞肺癌的II期临床研究

2015-11-17

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Clin Cancer Res：尼罗替尼对KIT突变的黑色素瘤的II期临床研究

2015-05-02

huiwelcome (审核中...)

前往app查看评论内容

#II期临床研究#

Clin Cancer Res：Palbociclib 对Rb+晚期乳腺癌的II期临床研究

2015-07-26

科室
- - 订阅+
  - 更多科室
工具
服务